Pfizer’s 20vPnC boosts immune response in pneumococcal disease trial

The vaccine candidate showed positive safety results to 20 S. pneumoniae serotypes in adults and infants. Credit: Angelo Esslinger on Pixabay.



  • Pfizer; 20vPnC